Linking genetic susceptibility to Crohnʼs disease with Th17 cell function: IL-22 serum levels are increased in Crohnʼs disease and correlate with disease activity and IL23R genotype status-Reference-Cited by-同舟云学术

Linking genetic susceptibility to Crohnʼs disease with Th17 cell function: IL-22 serum levels are increased in Crohnʼs disease and correlate with disease activity and IL23R genotype status

Published:2008-02 Issue:2 Volume:14 Page:204-212
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:Inflammatory Bowel Diseases

Author:

Schmechel Silke,Konrad Astrid,Diegelmann Julia,Glas Jürgen,Wetzke Martin,Paschos Ekaterini,Lohse Peter,Göke Burkhard,Brand Stephan

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Reference50 articles.

1. Unravelling the pathogenesis of inflammatory bowel disease

2. Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

3. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

4. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

5. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations

Cited by 172 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating potential novel therapeutic targets and biomarkers for ankylosing spondylitis using plasma protein screening;Frontiers in Immunology;2024-08-09

2. Transcriptome-wide association studies associated with Crohn’s disease: challenges and perspectives;Cell & Bioscience;2024-02-25

3. Increased type-I interferon level is associated with liver damage and fibrosis in primary sclerosing cholangitis;Hepatology Communications;2024-02-14

4. Challenges and opportunities in inflammatory bowel disease: from current therapeutic strategies to organoid-based models;Inflammation Research;2024-02-12

5. Combining pharmacometric models with predictive and prognostic biomarkers for precision therapy in Crohn's disease: A case study of brazikumab;CPT: Pharmacometrics & Systems Pharmacology;2023-10-06